Article

AIG gives $5 million to ORBIS for blindness prevention

New York-American International group Inc. (AIG) has given a $5 million grant to ORBIS International to sustain and continue the growth of the group's long-term blindness prevention programs in Vietnam, China, India, Bangladesh, Ethiopia, and Latin America.

New York-American International group Inc. (AIG) has given a $5 million grant to ORBIS International to sustain and continue the growth of the group's long-term blindness prevention programs in Vietnam, China, India, Bangladesh, Ethiopia, and Latin America.

Geoffrey Holland, ORBIS international executive director, said the fight against avoidable blindness requires comprehensive, long-term solutions and the country programs will build sustainable eye care infrastructures and services.

According to estimations by the World Health Organization nearly 37 million people worldwide are blind and 124 million people have such poor vision normal life is impossible. The catch is 75% of those people don't have to be blind and that is where ORBIS comes in.

AIG has been a big supporter of ORBIS, being involved with their Flying Eye Hospital and aiding in launching the country programs. The current program will run from October 2007 through September 2012. The partnership was announced at the 25th Anniversary celebration of ORBIS in New York city on March 1st 2007.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.